Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) have been assigned an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.

Brokers have set a 1-year consensus target price of $26.75 for the company, according to Zacks. Zacks has also assigned Verona Pharma PLC American Depositary Share an industry rank of 108 out of 265 based on the ratings given to its competitors.

Several research firms have issued reports on VRNA. Zacks Investment Research upgraded Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Tuesday, July 25th. Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Verona Pharma PLC American Depositary Share in a research note on Friday, September 8th.

Verona Pharma PLC American Depositary Share (NASDAQ VRNA) opened at 14.91 on Friday. Verona Pharma PLC American Depositary Share has a 52 week low of $11.03 and a 52 week high of $17.50. The company’s market cap is $164.96 million. The company has a 50-day moving average of $15.12 and a 200-day moving average of $13.40.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last posted its earnings results on Tuesday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.09). On average, equities analysts expect that Verona Pharma PLC American Depositary Share will post ($2.23) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/20/verona-pharma-plc-american-depositary-share-vrna-receives-average-recommendation-of-strong-buy-from-brokerages.html.

Hedge funds have recently modified their holdings of the company. Tekla Capital Management LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the second quarter worth about $3,211,000. Vivo Capital LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the second quarter worth about $8,208,000. Finally, FIL Ltd purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the second quarter worth about $873,000. Institutional investors and hedge funds own 30.16% of the company’s stock.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Get a free copy of the Zacks research report on Verona Pharma PLC American Depositary Share (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.